Stonegate Updates Coverage on Burcon Nutrascience Corporation (BU) FY26 Q1

Executive Summary

• Stonegate Capital Partners updated their coverage on Burcon Nutrascience Corporation, highlighting significant commercialization progress in Q1 FY26.
• The company achieved first commercial production of its next-generation Peazazz® C pea protein and debuted FavaPro fava protein at its Galesburg facility within 90 days of commissioning.
• Burcon secured a $6.8 million multi-year production agreement and reported a 44% year-over-year revenue increase to $0.34 million, despite margin pressures from facility startup costs.

Key Details

• Commercial Production Milestones:
  • Achieved first commercial production of Peazazz® C pea protein.
  • Debuted FavaPro fava protein.
  • Completed initial shipments of Peazazz® C during the quarter.
  • Received strong market reception and positive customer trials.
• Financial Performance (Q1 FY26):
  • Revenue rose 44% year-over-year to $0.34 million.
  • Startup costs at the Galesburg facility impacted margins, with expenses settling into "new normal" levels.
  • Company maintains a 2025 revenue target of $1-3 million.
• Strategic Agreements:
  • Entered into a $6.8 million multi-year production agreement.
  • The agreement provides baseline recurring revenue and underpins the 2025 revenue target.
• Operational Capabilities:
  • The Galesburg facility integrates proprietary protein technologies.
  • Enables scalable, versatile production across multiple plant-based proteins.
  • Operational flexibility allows the company to meet evolving customer needs quickly with consistent quality.
• Market Opportunity:
  • The company positions itself to unlock a total addressable pea protein market estimated between US$215 million and US$392 million.

Notable Quotes

• No direct quotes from the CEO or President were included in the provided text; the content consists of Stonegate Capital Partners' analysis and key takeaways.